Comparative Pharmacology
Head-to-head clinical analysis: PARACAINE versus POSIMIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARACAINE versus POSIMIR.
PARACAINE vs POSIMIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that reversibly blocks sodium channels in neuronal membranes, inhibiting nerve impulse conduction.
Bupivacaine, the active ingredient in POSIMIR, is an amide-type local anesthetic that blocks voltage-gated sodium channels in nerve cell membranes, inhibiting the generation and conduction of nerve impulses. POSIMIR is a bupivacaine extended-release liposomal formulation designed for sustained release at the surgical site.
10-20 mg orally every 4-6 hours as needed; maximum 80 mg/day.
Posimir (bupivacaine) is administered as a single intra-articular injection into the subacromial space following arthroscopic shoulder surgery. The recommended adult dose is 5 mL (66 mg) of the 1.32% solution.
None Documented
None Documented
Clinical Note
moderateProparacaine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Fluticasone propionate."
Clinical Note
moderateProparacaine + Clemastine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Clemastine."
Clinical Note
moderateProparacaine + Venlafaxine
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Venlafaxine."
Clinical Note
moderate2.5 hours; prolonged to 8 hours in cirrhosis due to reduced hepatic metabolism
Terminal elimination half-life is approximately 27 hours (range 16-38 hours), supporting once-daily dosing in clinical use.
Renal: 90% (70% unchanged, 20% as paracainol glucuronide); Biliary/Fecal: 10%
Primarily hepatic metabolism via CYP3A4 and CYP1A2 to inactive metabolites; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for >90% of total clearance.
Category C
Category C
Local Anesthetic
Local Anesthetic
Proparacaine + Nefazodone
"The risk or severity of adverse effects can be increased when Proparacaine is combined with Nefazodone."